PTCT insider plans sale of 1,286 common shares

PTC Therapeutics insider files to sell additional shares under Rule 144.

Rhea-AI Filing Summary

PTC Therapeutics insider files to sell additional shares under Rule 144. The filing covers a planned sale of 1,286 shares of common stock through Fidelity Brokerage Services on or about 01/08/2026, with an aggregate market value of approximately $98,313.54. These shares were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation.

Over the past three months, Mark Boulding has already sold 11,696 shares of common stock in four transactions, generating total gross proceeds of about $896,531.96. The notice also confirms that the seller represents not knowing any undisclosed material adverse information about the issuer’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the PTCT Form 144 filing disclose about upcoming share sales?

The Form 144 indicates an intent to sell 1,286 shares of PTC Therapeutics (PTCT) common stock through Fidelity Brokerage Services, with an aggregate market value of about $98,313.54, on or around 01/08/2026.

Who is selling PTCT shares in this Form 144 and how were they acquired?

The seller is Mark Boulding. The 1,286 shares to be sold were acquired on 01/07/2026 through restricted stock vesting from the issuer as compensation.

How many PTCT shares has the filer sold in the last three months?

Over the past three months, Mark Boulding has sold a total of 11,696 shares of PTCT common stock in four transactions dated 11/17/2025, 01/05/2026, 01/06/2026, and 01/07/2026.

What were the recent gross proceeds from PTCT share sales disclosed in the Form 144?

The four recent sales generated gross proceeds of $213,690.35, $171,190.18, $133,811.88, and $377,839.55, for total gross proceeds of about $896,531.96.

How many PTCT shares are outstanding according to this Form 144?

The filing reports that there are 80,288,305 shares of PTCT common stock outstanding.

What representation does the seller make about PTCT’s non-public information?

By signing the notice, the seller represents that he does not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 04:17 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001578852
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PTC THERAPEUTICS, INC.
SEC File Number	001-35969
Address of Issuer	500 WARREN CORPORATE CENTER DRIVE WARREN NEW JERSEY 07059
Phone	9082227000
Name of Person for Whose Account the Securities are To Be Sold	Boulding Mark Elliott
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1286	98313.54	80288305	01/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/07/2026	Restricted Stock Vesting	Issuer			1286	01/07/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	11/17/2025	2812	213690.35
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/05/2026	2266	171190.18
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/06/2026	1739	133811.88
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/07/2026	4879	377839.55

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	01/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Mark Boulding
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)